

July 2000

Principal Investigator	Department	Funding Agency	Title	Amount Awarded	Award Date
ATKINSON, MARK A.	PATHOLOGY & LABORATORY MED	SUB WITH COLUMBIA UNIVERSITY	PHASE I/II TRIAL OF HOKT3 GAMMA 1 (A1A-A1A) FOR TREATMENT OF NEW ONSET TYPE 1 DIABETES MELLITUS	\$24,718	07/31/00
BIRENBAUM, DALE S.	CTR FOR CLINICAL TRIALS RES	VIROPHARMA INC	A DBL-BL RNDMZD PLCB-CNTRL TRIAL OF A TABLET FORMULATION OF PLECONARIL IN THE TREATMENT OF VIRAL RESPIRATORY INFECTION	\$1,500	07/24/00
BRANTLY, MARK L.	MEDICINE	AVENTIS	DBL-BL RNDMZD PLCB-CNTRL DOSE ESCALATION STDY TO ASSES THE SAF & TOLERANCE OF ALPHA1-PROTEINASE INHIBITOR (HUMAN) DRY	\$92,184	07/28/00
BYRNE, BARRY J.	PEDIATRICS	AM HEART ASSOCIATION - FL	PRECLINICAL STUDY FOR GENETIC CORRECTION OF INHERITED CARDIOMYOPATHY	\$60,000	07/17/00
CONTI, JAMIE B.	MEDICINE	GUIDANT	VENTAK AICD	\$2,250	07/19/00
FLETCHER, LUCIA N.	NEUROSCIENCE	MUSCULAR DYSTROPHY ASSOCIATION	TARGETS FOR THERAPY IN THE CELLULAR PATHOGENESIS OF CMT NEUROPATHIES	\$61,192	07/31/00
GRANT, MARIA A.	PHARMACOLOGY & THERAPEUTICS	PHARMANET INC	TAK-373-SR, A RNDMZD DBL-BL PLCB-CNTRLD ASCENDING SINGLE-DOS PHS 1 STDY OF SAF TOLER PHARMACOKINETICS & PHARMACODYNAMICS	\$15,100	07/18/00
KENNEDY, LAURENCE	MEDICINE	EXOCELL INC	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TWO-YEAR STUDY OF THE EFFECT OF THE ANTI-GLYCATION AGENT EXO	\$5,200	07/25/00
MOLDAWER, LYLE L.	SURGERY	NATL INSTITUTES OF HEALTH	GENETIC DETERMINANTS OF TNFA MEDIATED LIVER APOPTOSIS	\$108,375	07/26/00
MOZINGO, DAVID W.	SURGERY	PPD DEVELOPMENT	AN OPEN LABEL STUDY TO EVALUATE THE INCIDENCE OF WOUND INFECTION IN PATIENTS REQUIRING A TEMPORARY COVERING	\$6,875	07/07/00

			FOR		
MUIR, DAVE F.	PEDIATRICS	U S ARMY	NF1 TUMOR SPECIFIC THERAPEUTIC MODELING	\$232,892	07/31/00
NARAYAN, SATYA	CANCER CENTER	NATL INSTITUTES OF HEALTH	INTERACTION OF APC AND P53 IN COLORECTAL CARCINOGENESIS	\$187,986	07/05/00
NELSON, DAVID R.	MEDICINE	SCHERING-PLOUGH CORP	A DOUBLE-BLIND PLACEBO CONTROLLED RANDOMIZED DOSE RANGING STUDY OF RECOMBINANT HUMAN INTERLEUKING-10 FOR THE TREATMENT	\$10,000	07/25/00
OH, SUK	PHYSIOLOGY	NATL INSTITUTES OF HEALTH	ROLE OF ALK-1 AS A MODULATOR FOR TGF-BETA SIGNALING ON ANGIOGENESIS	\$289,000	07/27/00
RESNICK, MICHAEL B.	PEDIATRICS	DEPT OF EDUCATION	CREATION OF AN EDUCATIONAL DATA WAREHOUSE FOR ASSESSING STUDENT GAINS, TEACHER EFFECTIVENESS, AND SCHOOL . .	\$419,310	07/07/00
SACKELLARES, JAMES C.	NEUROSCIENCE	NOVARTIS - UNITED STATES	A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MONOTHERAPY STUDY OF RUFINAMIDE IN INPATIENTS WITH REFRACTOR	\$9,926	07/14/00
SCOTT, EDWARD W.	CANCER CENTER	NATL INSTITUTES OF HEALTH	STEM CELL HOMING - A GENETIC MODEL	\$78,194	07/26/00
SHAPIRA, NATHAN A.	PSYCHIATRY	WARNER-LAMBERT COMPANY	STUDY OF PAGOCLONE IN PATIENTS WITH PANIC DISORDER	\$12,000	07/21/00
STAUD, ROLAND	MEDICINE	ARTHRITIS FOUNDATION	MODIFICATION OF TONIC AND EXPERIMENTAL PAIN IN FIBROMYALGIA SYNDROME	\$75,000	07/20/00
STEVENS, BRUCE R.	PHYSIOLOGY	AM HEART ASSOCIATION - FL	L-ARGININE MEMBRANE TRANSPORTERS IN INOS-COMPETENT BRAIN ASTROGLIAL CELLS	\$60,000	07/27/00
STREIFF, RICHARD R.	MEDICINE	WARNER-LAMBERT COMPANY	A MULTI-CTR ESCALATING-DOSE PHASE 1 STDY OF INTRAVENOUS DIETHYLNORSPERMINE (DENSPM) ADMIN DAILY FOR 5 DAYS AS A LOAD	\$12,000	07/10/00
TISHER, C. CRAIG	CTR FOR CLINICAL TRIALS RES	EPIX MEDICAL	PHASE II STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF ANGIOMARK IN	\$116,302	07/24/00

			SUBJECTS WITH VARYING DEGREES OF RENAL INSUFF		
ZOLOTUKHIN, SERGE	MOLECULAR GENETICS & MICROBIO	NATL INSTITUTES OF HEALTH	CYTOKINE GENE THERAPY AND OBESITY	\$144,500	07/27/00